Strategic Solutions for Infectious Disease That Reprice the Cognitive Work the Fee Schedule Undervalues
Infectious disease is one of medicine's most consultative specialties and one of its most poorly paid — a book built on complex E/M and inpatient consultation, not procedures. Fulcrum Health Partners advises ID physicians, OPAT and home-infusion programs, HIV and 340B practices, and hospital ID divisions on commercial rate strategy, infusion economics, and the coverage and stewardship stipends that fund the essential work no CPT code rewards.
Of ID revenue from cognitive E/M & consults, not procedures
$0
Direct CPT reimbursement for antimicrobial stewardship
80%
Of U.S. counties with no practicing ID physician
340B
Program economics central to HIV & ID drug margin
The Infectious Disease Reimbursement Landscape
The specialty that saves the most money is paid for the least of what it does.
ID lives on the wrong side of a fee schedule built for procedures — where the value is in the consult that prevents the readmission, the regimen that avoids the ICU, and the stewardship that never bills.
An infectious disease physician's day is dense with complex inpatient consultation, prolonged services, and high-acuity decision-making — work the physician fee schedule pays at a fraction of what a proceduralist earns for far less cognitive effort. E/M is the entire book, so every downcode, prolonged-service denial, and below-market commercial rate lands directly on the P&L, and time itself is chronically undervalued.
Yet the enterprise value ID creates is enormous and largely uncoded: outpatient parenteral antibiotic therapy (OPAT) and home-infusion coordination that empties inpatient beds, antimicrobial stewardship and infection prevention that hospitals depend on, tele-ID coverage that keeps rural facilities compliant, and HIV care whose 340B and long-acting injectable economics dwarf the visit. The same physician effort is worth dramatically more when the coverage stipend, infusion margin, and buy-and-bill are structured correctly — and that is precisely where Fulcrum works.
Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/MedPAC methodology and public payer data, 2024–2026.
Revenue Per ID Physician — Illustrative
Cognitive volume, low procedural pay, under-recognized value
Cognitive E/M & consults
Limited procedural
Tele-ID coverage
OPAT / infusion margin
Coverage & stewardship stipends
The visit is the floor, not the ceiling. Fulcrum quantifies the full stack — coded, contracted, infused, and subsidized.
Our Infectious Disease Advisory Solutions
Advisory organized around the economics you manage
Not a service menu — the reimbursement problems that decide infectious disease margin and enterprise value, and the strategy, analytics, and negotiation capabilities that resolve them.
01The Challenge — A cognitive book you can't negotiate without benchmarking
Contract Assessment & Reimbursement Benchmarking
We digitize and normalize every payer contract and fee schedule, then benchmark your ID reimbursement — office and inpatient E/M, prolonged services, and infusion administration — against Medicare and against market, quantifying exactly where an undervalued cognitive specialty is being underpaid and what the opportunity is worth.
Contract digitization
Fee schedule normalization
% of Medicare benchmarking
E/M & consult rate analysis
Infusion & drug-admin benchmarking
EOB & payment variance analysis
Prolonged-service capture review
Revenue opportunity quantification
Contract performance scoring
02The Challenge — Little leverage until scarcity is on the table
Managed Care Negotiations & Strategy
We build the positioning, data, and strategy to lift commercial rates on the E/M and consult book and to convert an ID physician shortage into hospital coverage and stewardship stipends payers and facilities will fund.
Commercial rate improvement
Coverage & stipend structuring
OPAT & infusion terms
Tele-ID coverage contracts
Escalation & executive strategy
Network participation strategy
03The Challenge — Infusion and stipend decisions made without modeling margin
Contract Modeling & Analytics
CPT- and drug-level modeling that turns claims and contracts into scenario analysis for the E/M book, OPAT and home-infusion margin, and buy-and-bill antimicrobials and long-acting injectables your executives can act on.
CPT-level reimbursement modeling
OPAT & infusion margin analysis
Buy-and-bill ASP+ modeling
Scenario & what-if analysis
Stipend vs. FFS trade-off modeling
Executive Power BI dashboards
04The Challenge — Negotiating blind to what competitors are paid
Payer Transparency & Market Rate Intelligence
Federal Transparency in Coverage data has transformed the negotiating table. We mine machine-readable rate files to show what competing ID groups and infusion providers are actually paid on consults and drug administration — and arm your team with it.
Transparency in Coverage analysis
Competitor rate benchmarking
Infusion & J-code rate positioning
Negotiation preparation
Peer comparison
Commercial opportunity sizing
05The Challenge — Effort spread evenly across unequal payers and facilities
Covered Lives & Market Intelligence
We map covered lives, payer penetration, referral patterns, and ID physician coverage gaps across your market — including rural facilities without on-site ID — so you prioritize the negotiations, coverage agreements, and OPAT opportunities that move the most margin.
When payers downcode consults, deny prolonged services, or block prior authorization on high-cost antimicrobials, antivirals, and long-acting injectables, we lead the interpretation, escalation, and enforcement — turning contractual entitlement into collected revenue.
Contract interpretation
Consult & E/M downcoding challenges
Prior-authorization escalation
High-cost drug denial appeals
Executive negotiation
Contract enforcement
07The Challenge — Earned revenue that never arrives
Underpayment Recovery & Revenue Integrity
Our analytics compare contracts, fee schedules, ASP-based drug allowables, and EOB/remittance data to detect variances across the E/M book and the infusion and buy-and-bill lines, quantify recoverable revenue, and fix the root cause so leakage stops.
Contract compliance auditing
Underpayment & variance detection
Drug-admin & ASP recovery
Automated EOB/remit analytics
Root-cause remediation
Revenue integrity programs
Reimbursement Intelligence in Action
Your ID economics, by practice profile
Fulcrum turns your claims, consult, and contract data into executive dashboards. Select a profile to explore a sample payer-mix and revenue view spanning cognitive fee-for-service, infusion, and coverage-stipend revenue.
Independent ID Group · Payer Mix & RevenueLive Sample
Payer Mix (by attributed encounters)
Net Revenue by Payer — Cognitive FFS vs. Infusion & Stipend
Cognitive E/M & consult net paymentsInfusion, buy-and-bill & coverage-stipend revenue
Illustrative sample dashboard. Fulcrum builds these from your practice-management, claims, consult-log, and contract data by CPT, J-code, payer, and facility.
The Forces Reshaping Infectious Disease Economics
The strategic questions every infectious disease leader now faces
Beyond the fee schedule, these are the dynamics that decide ID margin — and where Fulcrum builds the strategy.
01
The Undervaluation of Cognitive Care
A book anchored in E/M and inpatient consultation, systematically paid below the effort and acuity it carries — with no procedural revenue to cushion cuts.
02
The ID Workforce Shortage
Too few ID physicians and vast coverage gaps create real leverage for hospital coverage agreements, stewardship stipends, and tele-ID contracts.
03
OPAT & Home-Infusion Economics
Outpatient parenteral antibiotic therapy shifts care out of the hospital — and the infusion, drug, and coordination margin is only captured with the right contracts.
04
HIV Care, 340B & Long-Acting Injectables
340B interplay and buy-and-bill long-acting antiretrovirals make drug economics, not the visit, the dominant financial lever in HIV programs.
05
Unfunded Stewardship & Infection Prevention
Antimicrobial stewardship and infection prevention are mandated and essential but carry no CPT code — requiring hospital subsidy and stipend negotiation.
06
Prior Authorization on High-Cost Antimicrobials
Authorization friction on expensive antimicrobials, antivirals, and injectables delays care and strands revenue as CMS reforms reshape payer timelines.
Infectious Disease Reimbursement Calculator
See what a fully-structured ID book is worth
Model the annual uplift from moving your commercial rates on the E/M and inpatient-consult book toward market, then add OPAT and home-infusion margin and the hospital coverage and stewardship stipends the work already justifies.
Your inputs
Enter approximate figures — nothing is stored or transmitted.
$
%
$
$
Estimated annual reimbursement uplift
$0
Adjust the inputs to model your opportunity.
$0
Per $1M of consult revenue
$0
3-year cumulative
Directional estimate for discussion only. Combines commercial rate improvement on the cognitive E/M and consult book with OPAT and home-infusion margin and hospital coverage and stewardship stipends; HIV 340B and buy-and-bill drug economics are additive. A Fulcrum analysis models your actual contracts, payer mix, and facility agreements.
Client Outcomes
How Fulcrum helps — and what it's worth
Anonymized outcomes from Fulcrum engagements with infectious disease groups, OPAT programs, and hospital ID divisions.
Independent ID Group
22%
commercial rate improvement on the consult book
Situation: a consult-heavy group was paid barely above Medicare with no procedural revenue to offset it. Result: benchmarking exposed rates far below market and we repositioned and renegotiated the top commercial payers on E/M and prolonged services — lifting blended commercial reimbursement without adding a single encounter.
Hospital ID & Stewardship Division
$1.9M
annual coverage & stewardship stipend secured
Situation: mandated antimicrobial stewardship and infection-prevention work generated no billable revenue and was quietly subsidizing the hospital. Result: we quantified the avoided cost and readmission impact and structured a recurring coverage and stewardship stipend that funds the program.
OPAT & HIV / 340B Practice
$3.4M
infusion & buy-and-bill margin captured
Situation: OPAT was coordinated for free and long-acting injectable antiretrovirals were referred out. Result: we built the infusion contracts and buy-and-bill economics and aligned 340B, converting clinical coordination into recurring, high-margin revenue.
Why Infectious Disease Leaders Choose Fulcrum
The advisor that speaks infectious disease's economic language
Independent by design and fluent in the economics of a cognitive specialty — E/M and consults, OPAT and infusion, HIV and 340B, coverage and stewardship stipends — delivered by the people who do the work.
Independent Advisor
No networks, no downstream fees — only your economics.
Cognitive-Specialty Fluency
Fluent in the E/M and consult economics that fund ID.
Commercial Rate Benchmarking
Market and transparency data behind every ask.
OPAT & Infusion Analytics
Modeling margin down to the drug and the J-code.
National Payer Experience
Insight into payer policy in every market.
HIV & 340B Insight
Aligning 340B and buy-and-bill drug economics.
Coverage & Stipend Negotiation
Funding stewardship and tele-ID the work justifies.
Data-Driven Support
Dashboards and intelligence that clarify the path.
Fulcrum Intelligence
Infectious disease insights & analysis
Executive briefings on the forces moving ID economics — the undervaluation of cognitive care, OPAT and infusion margin, HIV and 340B, and coverage and stewardship stipends.
Let's Reprice the Work Infectious Disease Actually Does.
Whether you're renegotiating commercial rates on a cognitive book, building OPAT and infusion margin, aligning HIV and 340B economics, or negotiating hospital coverage and stewardship stipends, Fulcrum Health Partners delivers the reimbursement expertise infectious disease leaders rely on.
